Triple-negative breast cancer (TNBC) accounts for 10–20% of all breast cancers and is characterized by the absence of estrogen receptor, progesterone receptor, and HER2 amplification, leading to poorer prognoses compared to other subtypes [2,3]. Here, ERBB2 is linked to breast carcinoma.